Ardelyx Inc logo

Ardelyx Inc

ARDX
Healthcare|Biotechnology|USA
$5.28
-0.10 (-1.77%)
Tangible Book
$0.60

Upcoming Data Readouts (2)

Dec 2026
Est. completion
P2Synucleinopathy
Tenapanor in Synucleinopathy-Related Constipation
Feb 2027
Est. completion
P3Chronic Idiopathic Constipation (CIC)
A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults

Awaiting Results (2)

Trials past primary completion date but still active — data readout may be imminent.

Sep 2026
P3
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
NCT05643534
Jul 2026
P2
4-Week, Multi-center Dose-Ranging Study for the IBS-C in Pts. 6 to <12 Yrs
NCT06553547

Recent Press Releases